Wijzigingen in de richtlijn ‘Behandeling multipel myeloom 2018’

S. Zweegman; N. W. C. J. van de Donk; M-D. Levin; G. M. J.  Bos; P. Ypma; E. de Waal; M. J. Kersten; A. Croockewit; C.W. Choi; S. K. Klein; P. A. von dem Borne; A. Broyl; I. Nijhof; M. C. Minnema; P. Sonneveld

Wijzigingen in de richtlijn ‘Behandeling multipel myeloom 2018’

Translated title of the contribution: Update in the multiple myeloma treatment guideline 2018

S. Zweegman^*, N. W. C. J. van de Donk, M-D. Levin, G. M. J. Bos, P. Ypma, E. de Waal, M. J. Kersten, A. Croockewit, C.W. Choi, S. K. Klein, P. A. von dem Borne, A. Broyl, I. Nijhof, M. C. Minnema, P. Sonneveld

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

38 Downloads (Pure)

Abstract

Recently the guideline ‘Treatment multiple myeloma 2018’ was published. Below are the most important changes from the 2015 guideline. These changes concern the initial treatment of patients eligible for autologous stem cell transplantation, the initial treatment of patients who are not eligible for autologous stem cell transplantation and the patients with a relapse of the sickness. The changes are based on new clinical data that have become available from randomized phase 3 trials. The most recent version of the entire guideline can be found on the websites of both the NVvH and HOVON. The guideline will be adjusted per module. The expectation is that this will already happen in the coming months as several treatment combinations will be registered and hopefully also be available in the short term. This summary concerns patients who cannot be treated in a trial context. At all times treatment within a study context is preferable.

Translated title of the contribution	Update in the multiple myeloma treatment guideline 2018
Original language	Dutch
Pages (from-to)	108–114
Number of pages	7
Journal	Nederlands Tijdschrift voor Hematologie
Volume	15
Publication status	Published - Apr-2018

Access to Document

Wijzigingen in de richtlijn ‘Behandeling multipel myeloom 2018’Final publisher's version, 165 KBLicence: Taverne

https://www.ntvh.nl/journal-article/wijzigingen-in-de-richtlijn-behandeling-multipel-myeloom-2018/

Handle.net

Persistent link

Cite this

Zweegman, S., van de Donk, N. W. C. J., Levin, M.-D., Bos, G. M. J., Ypma, P., de Waal, E., Kersten, M. J., Croockewit, A., Choi, C. W., Klein, S. K., von dem Borne, P. A., Broyl, A., Nijhof, I., Minnema, M. C., & Sonneveld, P. (2018). Wijzigingen in de richtlijn ‘Behandeling multipel myeloom 2018’. Nederlands Tijdschrift voor Hematologie, 15, 108–114. https://www.ntvh.nl/journal-article/wijzigingen-in-de-richtlijn-behandeling-multipel-myeloom-2018/

@article{aaee5cb636e74126bf08d86c24e46b30,

title = "Wijzigingen in de richtlijn {\textquoteleft}Behandeling multipel myeloom 2018{\textquoteright}",

abstract = "Recently the guideline {\textquoteleft}Treatment multiple myeloma 2018{\textquoteright} was published. Below are the most important changes from the 2015 guideline. These changes concern the initial treatment of patients eligible for autologous stem cell transplantation, the initial treatment of patients who are not eligible for autologous stem cell transplantation and the patients with a relapse of the sickness. The changes are based on new clinical data that have become available from randomized phase 3 trials. The most recent version of the entire guideline can be found on the websites of both the NVvH and HOVON. The guideline will be adjusted per module. The expectation is that this will already happen in the coming months as several treatment combinations will be registered and hopefully also be available in the short term. This summary concerns patients who cannot be treated in a trial context. At all times treatment within a study context is preferable.",

author = "S. Zweegman and {van de Donk}, {N. W. C. J.} and M-D. Levin and Bos, {G. M. J.} and P. Ypma and {de Waal}, E. and Kersten, {M. J.} and A. Croockewit and C.W. Choi and Klein, {S. K.} and {von dem Borne}, {P. A.} and A. Broyl and I. Nijhof and Minnema, {M. C.} and P. Sonneveld",

year = "2018",

month = apr,

language = "Dutch",

volume = "15",

pages = "108–114",

journal = "Nederlands Tijdschrift voor Hematologie",

issn = "1572-1590",

}

Zweegman, S, van de Donk, NWCJ, Levin, M-D, Bos, GMJ, Ypma, P, de Waal, E, Kersten, MJ, Croockewit, A, Choi, CW , Klein, SK, von dem Borne, PA, Broyl, A, Nijhof, I, Minnema, MC & Sonneveld, P 2018, 'Wijzigingen in de richtlijn ‘Behandeling multipel myeloom 2018’', Nederlands Tijdschrift voor Hematologie, vol. 15, pp. 108–114. <https://www.ntvh.nl/journal-article/wijzigingen-in-de-richtlijn-behandeling-multipel-myeloom-2018/>

TY - JOUR

T1 - Wijzigingen in de richtlijn ‘Behandeling multipel myeloom 2018’

AU - Zweegman, S.

AU - van de Donk, N. W. C. J.

AU - Levin, M-D.

AU - Bos, G. M. J.

AU - Ypma, P.

AU - de Waal, E.

AU - Kersten, M. J.

AU - Croockewit, A.

AU - Choi, C.W.

AU - Klein, S. K.

AU - von dem Borne, P. A.

AU - Broyl, A.

AU - Nijhof, I.

AU - Minnema, M. C.

AU - Sonneveld, P.

PY - 2018/4

Y1 - 2018/4

N2 - Recently the guideline ‘Treatment multiple myeloma 2018’ was published. Below are the most important changes from the 2015 guideline. These changes concern the initial treatment of patients eligible for autologous stem cell transplantation, the initial treatment of patients who are not eligible for autologous stem cell transplantation and the patients with a relapse of the sickness. The changes are based on new clinical data that have become available from randomized phase 3 trials. The most recent version of the entire guideline can be found on the websites of both the NVvH and HOVON. The guideline will be adjusted per module. The expectation is that this will already happen in the coming months as several treatment combinations will be registered and hopefully also be available in the short term. This summary concerns patients who cannot be treated in a trial context. At all times treatment within a study context is preferable.

AB - Recently the guideline ‘Treatment multiple myeloma 2018’ was published. Below are the most important changes from the 2015 guideline. These changes concern the initial treatment of patients eligible for autologous stem cell transplantation, the initial treatment of patients who are not eligible for autologous stem cell transplantation and the patients with a relapse of the sickness. The changes are based on new clinical data that have become available from randomized phase 3 trials. The most recent version of the entire guideline can be found on the websites of both the NVvH and HOVON. The guideline will be adjusted per module. The expectation is that this will already happen in the coming months as several treatment combinations will be registered and hopefully also be available in the short term. This summary concerns patients who cannot be treated in a trial context. At all times treatment within a study context is preferable.

M3 - Article

SN - 1572-1590

VL - 15

SP - 108

EP - 114

JO - Nederlands Tijdschrift voor Hematologie

JF - Nederlands Tijdschrift voor Hematologie

ER -

Wijzigingen in de richtlijn ‘Behandeling multipel myeloom 2018’

Abstract

Access to Document

Handle.net

Fingerprint

Cite this